## Contents

### Program Faculty

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
</tr>
</tbody>
</table>

### Sponsorship and CME Credit

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ii</td>
</tr>
</tbody>
</table>

### CME Activity Assessment and Evaluation

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>iv</td>
</tr>
</tbody>
</table>

### Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference


### Erlotinib: Recent Clinical Results and Ongoing Studies in Non–Small Cell Lung Cancer

- Roman Perez-Soler .................................................. 4589s

### HKI-272 in Non–Small Cell Lung Cancer

- Kwok-Kin Wong .................................................. 4593s

### Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab

- Mark A. Socolnick .................................................. 4597s

### Is There a Role for Cetuximab in Non–Small Cell Lung Cancer?

- Daniel Morgensztern and Ramaswamy Govindan .......... 4602s

### Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors

- Philip D. Bonomi, Lela Buckingham, and John Coon .... 4606s

### Bevacizumab in Non–Small Cell Lung Cancer

- Alan Sandler .................................................. 4613s

### Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer

- Emer O. Hanrahan and John V. Heymach ................. 4617s

### Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer

- Gregory J. Riely and Vincent A. Miller ................. 4623s

### Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer

- Bruce E. Johnson, David Jackman, and Pasi A. Jänne .... 4628s

### Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations

- Julie E. Bauman, Keith D. Eaton, and Renato G. Martins ..... 4632s

### The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer

- Jeffrey A. Engelman .................................................. 4637s

### Enzastaurin, a Protein Kinase Cβ-Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer

- Roy S. Herbst, Yun Oh, Asavari Wagle, and Michael Lahn .... 4641s

### Incorporating Bortezomib into the Treatment of Lung Cancer

- Angela M. Davies, Primo N. Lara, Jr., Philip C. Mack, and David R. Gandara .......................... 4647s

### L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer

- Randeep Sangha and Charles Butts .......................... 4652s